Abstract:Endemic to Central Africa, loiasis, caused by the vector-borne worm Loa loa , affects approximately 10 million individuals. Clinical manifestations include transient angioedema (Calabar swellings), migration of the adult worm under the eye conjunctiva (eye worm) and less specific general symptoms. Loiasis presents a significant public health challenge because L . loa -infected individuals can develop serious adverse events after taking ivermectin, the drug used to combat onchocerciasis. In this context, alternative interventions and rigorous diagnostic approaches are needed. Diagnosing loiasis is challenging because its main clinical manifestations are sporadic and non-specific. The definitive diagnosis relies on identifying adult worms migrating beneath the conjunctiva, or microfilariae (pre-larvae) in blood smears. However, "occult loiasis" (infection without blood microfilariae) is frequent. Serological rapid antibody diagnostic tests (ARTs) can provide an alternative diagnostic method. We compared a novel ART simultaneously targeting onchocerciasis (IgG4 to Ov-16 and OvOC3261, test line 1) and loiasis (IgG4 to L1-SXP-1, test line 2), called IgG4-SXP-1 biplex test) to the already established Loa -ART (all IgG isotypes to Ll-SXP-1, called pan-IgG-SXP-1 test). Blood samples underwent both ARTs, read qualitatively and semi-quantitatively. Additionally, blood smears, skin snips, Kato-Katz method for soil-transmitted helminthiases identification and eosinophilia measurements were performed. Questionnaires gathered demographic details and loiasis-related signs. ARTs performance was compared using specific loiasis-related signs and microfilaremia as references. Discordances between the two ARTs were investigated using logistic regression models. Out of 971 participants, 35.4% had L . loa microfilaremia, 71.9% had already experienced loiasis-related signs, 85.1% were positive in the pan-IgG-SXP-1 test and 79.4% were positive in the IgG4-SXP-1 biplex test. In the microfilariae-positive population, the sensitivity of the rapid tests was 87.4% for the pan-IgG-SXP-1 test and 88.6% for the prototype IgG4-SXP-1 biplex test. Sensitivity was similar for both ARTs when using eye worm or Calabar swelling as references, but diagnostic performance varied based on microfilaremia levels and occult loiasis. Overall, IgG4-SXP-1 biplex test demonstrated a sensitivity of 84.1% and specificity of 47.6% for loiasis compared to the pan-IgG-SXP-1 test, leading to a Kappa coefficient estimated at 0.27 ± 0.03 for the qualitative results of the 2 ARTs. In the group that tested positive with the Pan-IgG test but negative with the IgG4-specific test, there was a lower prevalence of STH infection (p = 0.008) and elevated eosinophilia (p<0.001) compared to the general tested population. The sensitivity of each test was good (84–85%) but the diagnostic agreement between the two ARTs was poor, suggesting that IgG and IgG4 antibody responses should be interpreted differently. The assessment of the innovative rapid diagnostic IgG4-SXP-1 biplex test, designed for onchocerciasis and loiasis, shows encouraging sensitivity but underlines the necessity for further in vitro assessment. Loiasis, a disease caused by the parasite Loa loa impacting approximately 10 million people in Central Africa, causes transient angioedemas called Calabar swellings and eye worm episodes. Treatment is challenging, particularly in regions where onchocerciasis, another type of filariasis, is also prevalent. We tested a new kind of test that can detect both diseases at once and compared its performance with a previously available test for loiasis. We took blood samples from 971 people living in an area of Congo where loiasis is endemic. Out of the participants, 35.4% had L . loa pre-larvae in the blood–known as microfilariae, and 72.0% had experienced loiasis-related signs. The new test demonstrated promise in detecting the disease, albeit with some likelihood of false positives. Additionally, its performance varied according to the density of microfilariae in the blood. While the results exceeded expectations, further testing is essential to ensure its reliability. If validated, this test could prove instrumental in diagnosing both loiasis and onchocerciasis, offering a valuable tool for public health interventions in affected regions.

Inflammation and hemostasis in loiasis before and after ivermectin treatment: A biological pilot cross-sectional study

Inflammation and fibrinolysis in loiasis before and after ivermectin treatment: a biological pilot cross-sectional study

Eosinophils, basophils and myeloid-derived suppressor cells in chronic Loa loa infection and its treatment in an endemic setting

Analysis of diagnostic test outcomes in a large loiasis cohort from an endemic region: Serological tests are often false negative in hyper-microfilaremic infections

Association between arterial stiffness and Loa loa microfilaremia in a rural area of the Republic of Congo: A population-based cross-sectional study (the MorLo project)

Evaluation of a novel biplex rapid diagnostic test for antibody responses to Loa loa and Onchocerca volvulus infections

A novel antigen biomarker for detection of high-level of Loa loa microfilaremia

Focal spleen lesions in loiasis: A pilot study in Gabon

Evaluation of knowledge, attitude and practice towards loiasis in the rural community of Sindara, in central African Gabon

Clinical and epidemiological features of imported loiasis in Beijing: a report from patients returned from Africa

Colorimetric and Real-Time Loop-Mediated Isothermal Amplification (LAMP) for Detection of Loa loa DNA in Human Blood Samples

Reported healthcare-seeking of loiasis patients and estimation of the associated monetary burden in Gabon: Data from a cross-sectional survey

Variability of Loa loa microfilarial counts in successive blood smears and its potential implication in drug-related serious adverse events

[Long-lasting souvenir from Cameroon - Persistent, massive hypereosinophilia in amicrofilaremic infection with Loa loa]

Safety and short-term efficacy of a single dose of 2 mg moxidectin in Loa loa infected individuals: a double-blind, randomized ivermectin-controlled trial with ascending microfilarial densities

[Reliability evaluation in rural Congo of the calibrated blood smear technique to assess Loa loa microfilaremia level]

The design and development of a study protocol to investigate Onchocerca volvulus, Loa loa and Mansonella perstans-mediated modulation of the metabolic and immunological profile in lean and obese individuals in Cameroon

Efficacy and Safety of Albendazole 400 mg for 30 Days in Adult Patients with Low Microfilaremia: A Non-Inferiority Randomized Controlled Trial Compared to Ivermectin

Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle

IL-10 and Its Related Superfamily Members IL-19 and IL-24 Provide Parallel/Redundant Immune-Modulation in Loa loa Infection

Tentative analysis of biomarkers associated with filariasis in moungo division, littoral, cameroon.